Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Metagenomi Therapeutics, Inc. (NASDAQ: MGX)
MGX Stock Predictions and Ratings
WSX Rating:
SELL
WSX Forecast (1yr):
-1.50%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
400%
MGX Stock Analysis
MGX
PE Ratio:
MGX
PEG Ratio:
Not Available
MGX
Forward EPS Growth (12 month):
0.00%
MGX
PS Ratio:
2.2
MGX
PSG Ratio:
0.9
MGX
Forward Revenue Growth (12 month):
2.50%
MGX Articles
No data was found